November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
Teak leaf extract can help treat hair loss, and its effectiveness varies by geographic origin.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
March 2025 in “Molecules” Tectona grandis leaf extracts, especially with propylene glycol, may be promising for topical hair loss treatments.
February 2025 in “Iranian journal of pharmaceutical research”
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
June 2024 in “Journal of Drug Delivery Science and Technology” Nanocarrier-based treatments show promise for better hair growth in androgenetic alopecia but need more research.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
February 2024 in “Trends in Sciences” Store Tectona grandis leaf extracts in slightly acidic, light-protected conditions for best stability.
December 2023 in “International Journal of Pharmaceutics” New nanoparticles deliver plant extracts to hair follicles to treat conditions like hair loss and acne.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
June 2023 in “Journal of Cosmetic Dermatology” Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.